Detailed information for compound 183281

Basic information

Technical information
  • TDR Targets ID: 183281
  • Name: (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-2-(3-fluo ro-4-methoxyphenyl)-1-[2-[hexylsulfonyl(propy l)amino]ethyl]pyrrolidine-3-carboxylic acid
  • MW: 592.719 | Formula: C30H41FN2O7S
  • H donors: 1 H acceptors: 4 LogP: 2.97 Rotable bonds: 15
    Rule of 5 violations (Lipinski): 2
  • SMILES: CCCN(S(=O)(=O)CCCCCC)CCN1C[C@@H]([C@H]([C@@H]1c1ccc(c(c1)F)OC)C(=O)O)c1ccc2c(c1)OCO2
  • InChi: 1S/C30H41FN2O7S/c1-4-6-7-8-16-41(36,37)33(13-5-2)15-14-32-19-23(21-9-12-26-27(18-21)40-20-39-26)28(30(34)35)29(32)22-10-11-25(38-3)24(31)17-22/h9-12,17-18,23,28-29H,4-8,13-16,19-20H2,1-3H3,(H,34,35)/t23-,28-,29+/m1/s1
  • InChiKey: WELUHUKTVXHVBY-ZPJFYFFZSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-2-(3-fluoro-4-methoxy-phenyl)-1-[2-[hexylsulfonyl(propyl)amino]ethyl]pyrrolidine-3-carboxylic acid
  • (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-2-(3-fluoro-4-methoxyphenyl)-1-[2-[hexylsulfonyl(propyl)amino]ethyl]-3-pyrrolidinecarboxylic acid
  • (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-2-(3-fluoro-4-methoxyphenyl)-1-[2-(hexylsulfonyl-propylamino)ethyl]pyrrolidine-3-carboxylic acid
  • (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-2-(3-fluoro-4-methoxy-phenyl)-1-[2-(hexylsulfonyl-propyl-amino)ethyl]pyrrolidine-3-carboxylic acid
  • (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-2-(3-fluoro-4-methoxyphenyl)-1-[2-(hexylsulfonyl-propylamino)ethyl]-3-pyrrolidinecarboxylic acid

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Sus scrofa Endothelin receptor ET-B Starlite/ChEMBL References
Rattus norvegicus Endothelin receptor ET-A Starlite/ChEMBL References
Homo sapiens endothelin receptor type B Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Schistosoma japonicum ko:K04135 adrenergic receptor, alpha 1a, putative Endothelin receptor ET-B   443 aa 392 aa 23.5 %
Echinococcus granulosus pyroglutamylated rfamide peptide receptor Endothelin receptor ET-A   426 aa 412 aa 20.1 %
Onchocerca volvulus Endothelin receptor ET-B   443 aa 371 aa 20.5 %
Echinococcus multilocularis pyroglutamylated rfamide peptide receptor Endothelin receptor ET-A   426 aa 412 aa 21.1 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Echinococcus multilocularis arachidonate 5 lipoxygenase 0.0137 1 1
Schistosoma mansoni hypothetical protein 0.0115 0.4684 0.4684
Schistosoma mansoni lipoxygenase 0.0137 1 1

Activities

Activity type Activity value Assay description Source Reference
AUC (ADMET) = 2.8 ug ml-1 Total drug exposure is determined after oral dosing in rats. ChEMBL. 9379441
Cmax (ADMET) = 0.7 ug ml-1 Maximum drug concentration is determined after oral dosing in rats. ChEMBL. 9379441
F (ADMET) = 40 % Oral bioavailability in rat ChEMBL. 9379441
IC50 (binding) = 0.077 nM Binding assay performed using human Endothelin A receptor (hETA) expressed in chinese hamster ovary cells(CHO). ChEMBL. 9379441
IC50 (binding) = 0.077 nM Binding assay performed using human Endothelin A receptor (hETA) expressed in chinese hamster ovary cells(CHO). ChEMBL. 9379441
IC50 (binding) = 0.11 nM Ability to displace endothelin ([125I]-ET-1) from endothelin A receptor derived from MMQ cells of rodent. ChEMBL. 9379441
IC50 (binding) = 0.11 nM Ability to displace endothelin ([125I]-ET-1) from endothelin A receptor derived from MMQ cells of rodent. ChEMBL. 9379441
IC50 (functional) = 0.14 nM Ability of the compound to block the ET-1-induced hydrolysis of inositol phosphate in Endothelin A receptor of MMQ cells. ChEMBL. 9379441
IC50 (functional) = 0.14 nM Ability of the compound to block the ET-1-induced hydrolysis of inositol phosphate in Endothelin A receptor of MMQ cells. ChEMBL. 9379441
IC50 (binding) = 0.34 nM Ability to displace endothelin ([125I]-ET-3) from endothelin B receptor derived from cerebellar tissue of porcine. ChEMBL. 9379441
IC50 (binding) = 0.34 nM Ability to displace endothelin ([125I]-ET-3) from endothelin B receptor derived from cerebellar tissue of porcine. ChEMBL. 9379441
IC50 (binding) = 0.46 nM Ability to displace endothelin ([125I]-ET-1) from endothelin A receptor derived from MMQ cells of rodent. ChEMBL. 9379441
IC50 (binding) = 0.46 nM Ability to displace endothelin ([125I]-ET-1) from endothelin A receptor derived from MMQ cells of rodent. ChEMBL. 9379441
IC50 (binding) = 0.48 nM Binding assay performed using human Endothelin B receptor (hETB) expressed in chinese hamster ovary cells(CHO) ChEMBL. 9379441
IC50 (binding) = 0.48 nM Binding assay performed using human Endothelin B receptor (hETB) expressed in chinese hamster ovary cells(CHO) ChEMBL. 9379441
IC50 (functional) = 1.12 nM Ability of the compound to block the ET-1-induced hydrolysis of inositol phosphate in Endothelin B receptor of chinese hamster ovary(CHO) cells. ChEMBL. 9379441
IC50 (functional) = 1.12 nM Ability of the compound to block the ET-1-induced hydrolysis of inositol phosphate in Endothelin B receptor of chinese hamster ovary(CHO) cells. ChEMBL. 9379441
IC50 (binding) = 1.5 nM Ability to displace endothelin ([125I]-ET-3) from endothelin B receptor derived from cerebellar tissue of porcine. ChEMBL. 9379441
IC50 (binding) = 1.5 nM Ability to displace endothelin ([125I]-ET-3) from endothelin B receptor derived from cerebellar tissue of porcine. ChEMBL. 9379441
Ratio (binding) = 3.3 Ratio of endothelin A receptor and endothelin B receptor. ChEMBL. 9379441
Ratio (binding) = 3.3 Ratio of endothelin A receptor and endothelin B receptor. ChEMBL. 9379441
T1/2 (ADMET) = 3.3 hr Half-life is obtained after intravenous dosing of rats. ChEMBL. 9379441
T1/2 (ADMET) = 6.4 hr Half-life is obtained after oral dosing of rats. ChEMBL. 9379441

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.